Wei Zhou

Wei Zhou

Auto-generated profile, based on publicly available information

Wei Zhou

Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy/Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
WZWei Zhou
Wei Zhou
PFPeng Fang
Peng Fang
DYDongan Yu
Dongan Yu
HRHongyuan Ren
Hongyuan Ren
MYMeng You
Meng You
JSJingkang Shen
Jingkang Shen
Overexpression of nectin cell adhesion protein 4 correlates with cancer progression and poor prognosis in many human malignancies. Enfortumab vedotin (EV) is the first nectin-4–targeting antibody–drug conjugate (ADC) approved by the FDA for the treatment of urothelial cancer. However, inadequate efficacy has limited progress in the treatment of other solid tumors with EV. Furthermore, ocular, pulmonary, and hematologic toxic side effects are common in nectin-4–targeted therapy, which frequently results in dose reduction and/or treatment termination. Thus, we designed a second generation nectin-4–specific drug, 9MW2821, based on interchain-disulfide drug conjugate technology. This novel drug contained a site specifically conjugated humanized antibody and the cytotoxic moiety monomethyl auristatin E. The homogenous drug–antibody ratio and novel linker chemistry of 9MW2821 increased the stability of conjugate in the systemic circulation, enabling highly efficient drug delivery and avoiding off-target toxicity. In preclinical evaluation, 9MW2821 exhibited nectin-4–specific cell binding, efficient internalization, bystander killing, and equivalent or superior antitumor activity compared with EV in both cell line–derived xenograft and patient-derived xenograft (PDX) models. In addition, 9MW2821 demonstrated a favorable safety profile; the highest nonseverely toxic dose in monkey toxicologic studies was 6 mg/kg, with milder adverse events compared with EV. Overall, 9MW2821 is a nectin-4–directed, investigational ADC based on innovative technology that endowed the drug with compelling preclinical antitumor activity and a favorable therapeutic index. The 9MW2821 ADC is being investigated in a phase I/II clinical trial (NCT05216965 and NCT05773937) in patients with advanced solid tumors.


16 September 2024
Verified
Other
Open access
WZWei Zhou
Wei Zhou
PFPeng Fang
Peng Fang
DYDongan Yu
Dongan Yu
HRHongyuan Ren
Hongyuan Ren
MYMeng You
Meng You
JSJingkang Shen
Jingkang Shen
Binding specificity based on enzyme-linked immunosorbent assay.

27 November 2025
Verified
Other
Open access
WZWei Zhou
Wei Zhou
PFPeng Fang
Peng Fang
DYDongan Yu
Dongan Yu
HRHongyuan Ren
Hongyuan Ren
MYMeng You
Meng You
JSJingkang Shen
Jingkang Shen
Antibody-dependent cell-mediated cytotoxicities of MW282 mAb, 9MW2821, and enfortumab vedotin